Conflicted psychiatrist leaves Emory

The Emory University psychiatry researcher who failed to report hundreds of thousands of dollars in pharmaceutical company payouts while receiving millions of dollars in funding from the National Institutes of Health to study the company's anti-depressant drugs is leaving the university, according to the linkurl:__Atlanta Journal-Constitution__.;http://www.ajc.com/health/controversial-emory-researcher-leaving-179261.html?cxtype=rss_news_128746 linkurl:Charles Nemeroff,;http://www.psychiatry.emo

Bob Grant
Bob Grant

Bob Grant is Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.

View full profile.


Learn about our editorial policies.

Nov 1, 2009
The Emory University psychiatry researcher who failed to report hundreds of thousands of dollars in pharmaceutical company payouts while receiving millions of dollars in funding from the National Institutes of Health to study the company's anti-depressant drugs is leaving the university, according to the linkurl:__Atlanta Journal-Constitution__.;http://www.ajc.com/health/controversial-emory-researcher-leaving-179261.html?cxtype=rss_news_128746 linkurl:Charles Nemeroff,;http://www.psychiatry.emory.edu/NeuropsychopharmacologyLaboratory/Charles%20Nemeroff.htm# a renowned depression researcher, failed to disclose to Emory approximately $800,000 in payments he received from drug maker GlaxoSmithKline (GSK) while he was the principal investigator (PI) on a multi-million dollar grant from the NIH to study five GSK antidepressants. Amid an investigation conducted by Emory, Nemeroff stepped down from his position as chairman of the psychiatry department last October. Later that month, the psychiatrist stepped down as PI from the $9.3 million NIH grant as the Senate probed his failure to disclose income from GSK, and the NIH froze funding on the five-year grant. Emory officials told the __Atlanta Journal-Constitution__ that...
lions of dollars in funding from the National Institutes of Health to study the company's anti-depressant drugs is leaving the university, according to the linkurl:__Atlanta Journal-Constitution__.;http://www.ajc.com/health/controversial-emory-researcher-leaving-179261.html?cxtype=rss_news_128746 linkurl:Charles Nemeroff,;http://www.psychiatry.emory.edu/NeuropsychopharmacologyLaboratory/Charles%20Nemeroff.htm# a renowned depression researcher, failed to disclose to Emory approximately $800,000 in payments he received from drug maker GlaxoSmithKline (GSK) while he was the principal investigator (PI) on a multi-million dollar grant from the NIH to study five GSK antidepressants. Amid an investigation conducted by Emory, Nemeroff stepped down from his position as chairman of the psychiatry department last October. Later that month, the psychiatrist stepped down as PI from the $9.3 million NIH grant as the Senate probed his failure to disclose income from GSK, and the NIH froze funding on the five-year grant. Emory officials told the __Atlanta Journal-Constitution__ that Nemeroff had not officially submitted his resignation as of last Friday (30th October), but that they were contacted by the institution that is hiring Nemeroff. They did not disclose what institution that was, but said that the university would issue an official announcement regarding Nemeroff's departure sometime today (2nd November). Ed Silverman over at the __Pharmalot__ blog linkurl:reported;http://www.pharmalot.com/2009/10/amid-inquiries-nemeroff-looks-beyond-emory/ last week that the University of Miami's Miller School of Medicine would be Nemeroff's new home, citing "sources familiar with the school."
**__Related stories:__***linkurl:NIH to act on conflicts within 1 year;http://www.the-scientist.com/blog/display/55264/
[5th December 2008]*linkurl:NIH $ frozen amid conflict probe;http://www.the-scientist.com/blog/display/55088/
[14th October 2008]*linkurl:Emory psychiatrist steps down;http://www.the-scientist.com/blog/display/55072/
[6th October 2008]

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?